Novo signs two drug pacts | Chemical & Engineering News
Volume 84 Issue 12 | p. 21 | Concentrates
Issue Date: March 20, 2006

Novo signs two drug pacts

Department: Business

Novo Nordisk has licensed antibody technology from Durham, N.C.-based Argos Therapeutics for the development of drugs to treat systemic immune disorders. The deal could be worth up to $69 million for Argos, which will receive up-front and milestone payments, as well as royalties on any drugs developed through its technology. Using its dendritic cell-based technology platform, Argos has found monoclonal antibodies that target INF-alpha, which is vital to the onset and maintenance of lupus. Separately, Novo has signed an agreement to study the use of Nastech Pharmaceutical's molecular biology-based drug delivery technology with several of its compounds.

Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment